Differences

This shows you the differences between two versions of the page.

--- pharmaceutical_companies:glaxosmithkline [2022/04/28 17:47]
liam [Research Funding]
+++ pharmaceutical_companies:glaxosmithkline [2022/10/06 18:25] (current)
pamela [[[:Google]] Partnership]
@@ Line 13: / Line 13: @@
 ==== Research Funding ====
-On November 10, 2011, GSK announced the launch of the $50 million GSK Canada Life Sciences Innovation Fund.((Robinson, A., & Minicucci, D. (2011, November 10). //GlaxoSmithKline Inc. Launches $50 Million Life Sciences Innovation Fund in Canada.// Wayback Machine; GlaxoSmithKline. https://web.archive.org/web/20160505194118/http://ca.gsk.com/media/525823/2011-11-10.pdf)) The purpose of the national fund was to advance the commercialization of scientific innovation in Canada by investing in early stage breakthrough research. The fund planned to identify strategic investment opportunities within Canada’s life sciences industry including academic and health institutions, translational research centres and start-up companies.
+On November 10, 2011, GSK announced the launch of the $50 million GSK Canada Life Sciences Innovation Fund to advance the commercialization of scientific innovation in Canada by investing in early stage breakthrough research.((Robinson, A., & Minicucci, D. (2011, November 10). //GlaxoSmithKline Inc. Launches $50 Million Life Sciences Innovation Fund in Canada.// Wayback Machine; GlaxoSmithKline. https://web.archive.org/web/20160505194118/http://ca.gsk.com/media/525823/2011-11-10.pdf))
+==== Google Partnership ====
+{{ :pharmaceutical_companies:gsk_google_verily.png?400|}}
+Google Parent and GlaxoSmithKline Are Creating a $715 Million Bioelectronics Firm.
+GSK and [[:Google]] Alphabet's Verily create $715M joint venture in bioelectronics
+by Ben Adams | Augist 1, 2016
+GlaxoSmithKline ($GSK) has announced a major new joint venture with [[:Verily]] --once [[:Google Life Sciences]] --as the two join forces with the hope of creating the first generation of bioelectronic medicines for chronic diseases.
+GSK has been working on this bioelectronic approach since 2012--an approach that aims to disrupt certain electronic signals in the body through tiny implanted devices in the hope of altering the pathways of a number of diseases and conditions.
+It’s stumped up around $50 million in VC cash in that time, but today is taking a much larger leap into this burgeoning area where tech meets biology by putting down £540 million ($715 million) over the next 7 years into a JV with Verily, which will focus on building devices that target arthritis, diabetes and asthma.
+Verily, a part of [[:Alphabet]] ($GOOG) and graduating from its secretive [[:Google X division]], has recently become its own unit, with a focus on big data and devices, such as a "smart" contact lens and surgical robots.
+The company has already attracted the attention of a number of Big Pharmas, having tie-ups with [[:Sanofi]] ($SNY) in diabetes and already signing a JV with [[:Johnson & Johnson]] ($JNJ) to create a company known as Verb Surgical, which aims to make new kinds of robotic surgical systems. It also has a deal with [[:Dexcom]] ($DXCM) that has seen the two publicly declare their ambition to launch a mini glucose monitor by 2018.
+Its latest iteration, called [[:Galvani Bioelectronics]] (after the Italian 18th century pioneer in the field of bioelectricity Luigi Aloisio Galvani), will be 55% owned by GSK and 45% by Verily. The R&D arms will be split between GSK’s research base in Stevenage, U.K., and Verily’s facilities in South San Francisco--but its official headquarters will be in the U.K. ((https://web.archive.org/web/20160802185529/https://www.fiercebiotech.com/medical-devices/gsk-and-google-s-verily-create-715m-joint-venture-bioelectronics))
 ==== COVID-19 ====